# US 2023/0055121 A1 · Aqueous suspension composition containing sirolimus or salt thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0055121 A1
- Document ID: US20230055121A1
- Status: Published application
- Kind: A1
- Application number: 17/784,327
- Filed: 2020-12-25
- Published: 2023-02-23
- Earliest claimed: 2019-12-26
- Assignees: Santen Pharmaceutical Co., Ltd.
- Applicants: Santen Pharmaceutical Co., Ltd.
- Inventors: Toyomi FUJISAWA; Ayaka AKUTAGAWA
- Web page: https://patentgrep.com/patent/US20230055121A1

## CPC

- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61P 27/02: Ophthalmic agents
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/10: Dispersions; Emulsions
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/38: Cellulose; Derivatives thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The purpose of the present invention is to provide an aqueous suspension composition comprising poorly water-soluble sirolimus or a salt thereof for ophthalmology, in particular, used for topical administration, such as a less invasive eye drop. The present invention is an ophthalmic aqueous suspension composition comprising sirolimus or a salt thereof and a surfactant, wherein the aqueous suspension composition has a pH of 4 to 6.

## Claims

### Claim 1

An ophthalmic aqueous suspension composition comprising sirolimus or a salt thereof and a surfactant, wherein
the aqueous suspension composition has a pH of 4 to 6.

### Claim 2 (depends on 1)

The aqueous suspension composition according to claim 1, wherein a content ratio of the surfactant to sirolimus or a salt thereof is more than 0.01 parts by weight based on 1 part by weight of a content of sirolimus or a salt thereof, and
sirolimus or a salt thereof in the aqueous suspension composition has an average particle size of 45 μm or less.

### Claim 3 (depends on 1)

The aqueous suspension composition according to claim 1, wherein a content ratio of the surfactant to sirolimus or a salt thereof is more than 0.01 parts by weight based on 1 part by weight of a content of sirolimus or a salt thereof, and
sirolimus or a salt thereof in the aqueous suspension composition has an average particle size of 15 μm or less.

### Claim 4 (depends on 1)

The aqueous suspension composition according to claim 1, wherein a content ratio of the surfactant to sirolimus or a salt thereof is more than 0.01 parts by weight based on 1 part by weight of a content of sirolimus or a salt thereof, and
sirolimus or a salt thereof in the aqueous suspension composition has an average particle size of 10 μm or less.

### Claim 5 (depends on 1)

The aqueous suspension composition according to claim 1, wherein the aqueous suspension composition has a pH of 5.

### Claim 6 (depends on 1)

The aqueous suspension composition according to claim 1, wherein a content of sirolimus or a salt thereof is from 0.01 to 1% (w/v).

### Claim 7 (depends on 1)

The aqueous suspension composition according to claim 1, wherein sirolimus or a salt thereof has an average particle size of 2.5 μm or less.

### Claim 8 (depends on 1)

The aqueous suspension composition according to claim 1, wherein the surfactant is one or more selected from the group consisting of polyoxyethylene fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene hydrogenated castor oils, polyoxyl castor oils, and polyoxyethylene alkyl ether phosphates.

### Claim 9 (depends on 1)

The aqueous suspension composition according to claim 1, wherein the surfactant is one or more selected from the group consisting of polyoxyl 40 stearate, polysorbate 80, polyoxyl 35 castor oil, and sodium polyoxyethylene cetyl ether phosphate.

### Claim 10 (depends on 1)

The aqueous suspension composition according to claim 1, wherein the surfactant is polysorbate 80.

### Claim 11 (depends on 1)

The aqueous suspension composition according to claim 1, comprising a dispersant.

### Claim 12 (depends on 11)

The aqueous suspension composition according to claim 11, wherein the dispersant is one or more selected from the group consisting of cellulosic polymers, polyalcohols, polyvinylpyrrolidone, and mucopolysaccharides.

### Claim 13 (depends on 1)

The aqueous suspension composition according to claim 1, further comprising one or more selected from the group consisting of buffering agents, tonicity agents, stabilizers, antioxidants, preservatives, and pH adjusters.

### Claim 14 (depends on 13)

The aqueous suspension composition according to claim 13, wherein the preservatives are one or more selected from the group consisting of invert soaps, parabens, sorbic acid or salts thereof, chlorobutanol, and silver nitrate.

### Claim 15 (depends on 1)

The aqueous suspension composition according to claim 1, which is an eye drop.

### Claim 16

An ophthalmic aqueous suspension composition comprising sirolimus or a salt thereof and polysorbate 80, wherein
a content of sirolimus or a salt thereof is from 0.01 to 1% (w/v),
a content ratio of the polysorbate 80 to sirolimus or a salt thereof is from 0.1 to 10 parts by weight based on 1 part by weight of a content of sirolimus or a salt thereof,
sirolimus or a salt thereof in the aqueous suspension composition has an average particle size of 2.5 μm or less, and
the aqueous suspension composition has a pH of 4 to 6.

### Claim at position 17

-20. (canceled)
